DIAG301-0416: Oncology and Tumor Pathology II
The first hour of lecture will be presented with text
and the second hour of lecture will be presented using audio.
Enrollment is closed.
Presenters:
Dr. med. vet. habil. Matti Kiupel, PhD, DACVP
Craig A. Clifford, DVM, MS, DACVIM (Oncology)
Phil Bergman, DVM, MS, PhD, DACVIM (Oncology)
Rebecca Smedley, DVM, MS, DACVP
Course Open: April 5-May 27, 2016
Real Time Sessions (RTS): Tuesdays, April 12, 19, 26, May 3, 10, and 17, 2016; 8:00-10:00 pm ET (USA)
Course RTS Times in Your Area:
World Clock Converter
Practice Sessions: In order to prepare you for a successful experience
in your CE course, we request you attend a Practice Session prior to the first
Real Time Session. Please arrive promptly at the start time; each Practice Session
is up to 1 hour in length.
For more information, please visit the
CE Practice Area.
*The presenters for this course will be using audio which will require you to have a headset or speakers to listen.
If you have any concerns regarding your computer's audio capabilities, please be sure to attend
one of the Practice Sessions.
Level and Prerequisites:
This
advanced course will be open to veterinarians, actively interested in
canine and feline oncology and tumor pathology. Participants should have a strong interest
and/or experience in oncology.
VIN CE Course: Open to veterinarians.
This course is approved by RACE for veterinarians. (RACE 22-21575)
Course Information:
This is the second of two modules on oncology and tumor pathology. This course can be taken
independently of the first module (DIAG300-0415: Oncology and Tumor Pathology I) which will
be offered again in April of 2017.
This course will familiarize participants with the current state of tumor diagnosis and prognosis
as well as therapeutic interventions. This course will cover canine/feline histiocytic diseases,
canine/feline soft tissue sarcomas, canine/feline osteosarcoma, canine melanomas,
and canine/feline mammary tumors.
The pathology segments will discuss the classical histologic criteria to diagnosis and prognosticate
neoplastic diseases including the newest grading systems. Furthermore, the participants will be
introduced to modern molecular pathology tests that further our prognostic capabilities and help
determine therapeutic protocols, such as immunohistochemical tumor diagnostic and prognostic panels.
From the clinical oncology perspective, this course will familiarize the participants with the
basic surgical aspects of veterinary oncology including: routine staging of patients, proper
aspirate and biopsy techniques as well as the preferred approach for a definitive surgery
when appropriate. The remaining lectures are designed to highlight the etiology (with an emphasis
on the latest research regarding genetic aspects of the specific tumor type) and typical signalment,
clinical signs, staging, diagnosis, therapy and prognosis for specific histologies. A special emphasis
will be provided on the latest research for each cancer type regarding the use of novel targeted
therapies when appropriate.
Week 1 (Real Time Session April 12, 2016):
Tumor Pathology and Clinical Oncology Basics
Presenters: Dr. med. vet. habil. Matti Kiupel, PhD, DACVP
Craig A. Clifford, DVM, MS, DACVIM (Oncology)
Phil Bergman, DVM, MS, PhD, DACVIM (Oncology)
Rebecca Smedley, DVM, MS, DACVP
Format: Text/Audio
Objectives: Upon completion of this session, the participant should be able to
- submit high quality tumor biopsy samples for microscopic evaluation,
margin evaluation, and advanced molecular testing from various organs.
- recognize the current histologic grading schemes for the neoplastic entities discussed.
- understand and integrate advanced molecular testing to determine tumor prognosis
and for therapeutic decision making.
- demonstrate an understanding of the indications for and differences between
incisional and excisional biopsies.
Week 2 (Real Time Session April 19, 2016):
Canine/Feline Histiocytic Diseases
Presenters: Dr. med. vet. habil. Matti Kiupel, PhD, DACVP
Craig A. Clifford, DVM, MS, DACVIM (Oncology)
Rebecca Smedley, DVM, MS, DACVP
Format: Text/Audio
Objectives: Upon completion of this session, the participant should be able to
- demonstrate an understanding of the difference between staging and grading
while also gaining an appreciation for general staging recommendations
for canine/feline histiocytic diseases.
- recognize the etiology (with an emphasis on the latest research regarding
genetic aspects of the specific tumor type) and typical signalment, clinical signs,
staging, diagnosis, therapy and prognosis for canine/feline histiocytic diseases.
- demonstrate an appreciation for the latest research regarding the use
of novel targeted therapies when appropriate.
Week 3 (Real Time Session April 26, 2016):
Canine/Feline Soft Tissue Sarcoma
Presenters: Dr. med. vet. habil. Matti Kiupel, PhD, DACVP
Craig A. Clifford, DVM, MS, DACVIM (Oncology)
Phil Bergman, DVM, MS, PhD, DACVIM (Oncology)
Rebecca Smedley, DVM, MS, DACVP
Format: Text/Audio
Objectives: Upon completion of this session, the participant should be able to
- demonstrate an understanding of the difference between staging and grading
while also gaining an appreciation for general staging recommendations
for canine/feline soft tissue sarcoma.
- recognize the etiology (with an emphasis on the latest research regarding
genetic aspects of the specific tumor type) and typical signalment, clinical signs,
staging, diagnosis, therapy and prognosis for canine/feline soft tissue sarcoma.
- demonstrate an appreciation for the latest research regarding the use
of novel targeted therapies when appropriate.
Week 4 (Real Time Session May 3, 2016):
Canine/Feline Osteosarcoma
Presenters: Dr. med. vet. habil. Matti Kiupel, PhD, DACVP
Phil Bergman, DVM, MS, PhD, DACVIM (Oncology)
Rebecca Smedley, DVM, MS, DACVP
Format: Text/Audio
Objectives: Upon completion of this session, the participant should be able to
- demonstrate an understanding of the difference between staging and grading
while also gaining an appreciation for general staging recommendations
for canine/feline osteosarcoma.
- recognize the etiology (with an emphasis on the latest research regarding
genetic aspects of the specific tumor type) and typical signalment, clinical signs,
staging, diagnosis, therapy and prognosis for canine/feline osteosarcoma.
- demonstrate an appreciation for the latest research regarding the use
of novel targeted therapies when appropriate.
Week 5 (Real Time Session May 10, 2016):
Canine Melanoma
Presenters: Dr. med. vet. habil. Matti Kiupel, PhD, DACVP
Craig A. Clifford, DVM, MS, DACVIM (Oncology)
Phil Bergman, DVM, MS, PhD, DACVIM (Oncology)
Rebecca Smedley, DVM, MS, DACVP
Format: Text/Audio
Objectives: Upon completion of this session, the participant should be able to
- demonstrate an understanding of the difference between staging and grading
while also gaining an appreciation for general staging recommendations
for canine melanoma.
- recognize the etiology (with an emphasis on the latest research regarding
genetic aspects of the specific tumor type) and typical signalment, clinical signs,
staging, diagnosis, therapy and prognosis for canine melanoma.
- demonstrate an appreciation for the latest research regarding
the use of novel targeted therapies when appropriate.
Week 6 (Real Time Session May 17, 2016):
Canine/Feline Mammary Tumors
Presenters: Dr. med. vet. habil. Matti Kiupel, PhD, DACVP
Craig A. Clifford, DVM, MS, DACVIM (Oncology)
Phil Bergman, DVM, MS, PhD, DACVIM (Oncology)
Rebecca Smedley, DVM, MS, DACVP
Format: Text/Audio
Objectives: Upon completion of this session, the participant should be able to
- demonstrate an understanding of the difference between staging and grading
while also gaining an appreciation for general staging recommendations
for canine/feline mammary tumors.
- recognize the etiology (with an emphasis on the latest research regarding
genetic aspects of the specific tumor type) and typical signalment, clinical signs,
staging, diagnosis, therapy and prognosis for canine/feline mammary tumors.
- demonstrate an appreciation for the latest research regarding the use of
novel targeted therapies when appropriate.
Successful completion (scoring 80% or better) on the end-of-course test is required
to earn a certificate of completion for the course.
To learn more about the requirements for earning a CE certificate, please refer to
Receiving Your CE Credit and Course Completion Certificate.
Course Materials: Course materials will be available
in the course library prior to each Real Time Session.
Required Textbook(s): There is no required textbook for this course.
About the Presenters:
Dr. Matti Kiupel is a board certified veterinary pathologist
with extensive experience in tumor pathology and molecular pathology. He is
Professor at Michigan State University and Section Chief of Anatomic Pathology
at the Diagnostic Center for Population and Animal Health. Dr. Kiupel is an
internationally renowned speaker and has won numerous lecturer awards and authored
more than 200 peer-reviewed scientific publications. Together with Dr. Smedley
he is editor of the WSAVA online atlas of Tumor Classification of Domestic Animals.
Dr. Phil Bergman is a medical oncologist and the Director of
Clinical Studies for VCA at the Katonah-Bedford Veterinary Center, a 24/7
Specialty/ER center in Westchester County, NY. He is the principal veterinary
investigator for the recently fully licensed canine melanoma vaccine (Oncept)
available from Merial. Dr. Bergman is an adjunct faculty member of the Memorial
Sloan-Kettering Cancer Center and will continue/expand his cancer vaccine program
within the VCA Antech network.
Dr. Craig Clifford is a medical oncologist and the Director of
Clinical Studies for Hope Veterinary Specialists in Malvern PA. Dr. Clifford is
a well renowned oncologist who has authored/co-authored over 30 papers and book chapters.
He was responsible for the creation of resident review sponsored by the Veterinary
Cancer Society and the Northeast Veterinary Co-operative Oncology Group.
He is a frequent lecturer at major veterinary meetings in the USA and internationally.
Dr. Clifford is currently serving on the VCS executive board, the ACVIM Exam Rating
Committee, the Residency Training and Credentials Committee and is the Co-chair of
the Standards of Excellence in Residency Education Task Force.
Rebecca Smedley is a board certified veterinary pathologist
with extensive experience in tumor pathology and molecular pathology. She is an
Academic Specialist at the Diagnostic Center for Population and Animal Health at
Michigan State University. Dr. Smedley is first and collaborating author on a large
number of peer-reviewed scientific publications in the field of tumor pathology and
has been an invited speaker on these topics to national and international scientific
conferences. Together with Dr. Kiupel she is editor of the WSAVA online atlas of Tumor
Classification of Domestic Animals.
Total CE Credit: 12
Tuition: Member $252 ($227 early bird special if enrolled by March 22, 2016)
Non-Member $374 ($337 early bird special if enrolled by March 22, 2016)
*To ensure participants are ready and prepared for classes,
enrollment will close on April 12, 2016 at 5 pm ET (USA)
or when the maximum number of participants is reached.
*For more information on how online CE works, see the
Participant Resource Center.
To Enroll:
Enrollment is closed.
- Enrollment qualifications: VIN CE courses are open to
VIN member and non-member veterinarians. Veterinarians enrolling in a VSPN CE course
must be a VIN member. Veterinary support staff must be a VSPN member to enroll in a
VSPN CE or a VIN CE course open to VSPN member enrollment.
- Each enrollee must be able to receive emails from @vspn.org
and @vin.com addresses. Email is our major form of communication with participants;
personal emails are highly recommended rather than clinic/hospital email addresses.
- Each person is individually responsible for his/her own registration.
To ensure that all information received is secure and correct, please do not enroll
for a course on behalf of another individual.
- For further assistance call 800-846-0028 ext. 797 or email
CEonVIN@vin.com.
Please include the course title, your full name, and contact information in your correspondence.
"This program (22-21575) is approved by the AAVSB RACE to offer a
total of 12 CE Credits, with a maximum of 12 CE Credits being available to any individual veterinarian.
This RACE approval is for the subject matter categories of:
Scientific,
using the delivery method of Interactive-Distance: (Web-based, Teleconference or Audio-Conference).
This approval is valid in jurisdictions which recognize AAVSB RACE; however, participants are
responsible for ascertaining each board's CE requirements."
Course withdrawal and refund policy: A complete refund of the paid course price will be
issued when your withdrawal request is received prior to the listed start date of the course.
If you wish to withdraw after the start date please contact the VIN office 800-846-0028 ext. 797
to discuss eligibility for a pro-rated refund.
* Note: To ensure rapid handling of your request for withdrawal, we recommend that you
call the VIN office at 800-846-0028 ext. 797.
*For more information on VIN's upcoming CE courses, check the
VIN Course Catalog.
Katherine James, DVM, PhD, DACVIM (SAIM)
VIN Education Coordinator
VIN CE Services:
CEonVIN@vin.com
800-846-0028 or 530-756-4881; ext. 797
or direct line to VIN/VSPN from the United Kingdom: 01 45 222 6154
or direct line to VIN/VSPN from Australia: 02 6145 2357
800.700.4636 | CEonVIN@vin.com | 530.756.4881 | Fax: 530.756.6035
777 West Covell Blvd, Davis, CA 95616
Copyright 2002, Veterinary Information Network, Inc.
|
